HK1050486A1 - Therapeutic combinations of fatty acids - Google Patents
Therapeutic combinations of fatty acidsInfo
- Publication number
- HK1050486A1 HK1050486A1 HK03102680A HK03102680A HK1050486A1 HK 1050486 A1 HK1050486 A1 HK 1050486A1 HK 03102680 A HK03102680 A HK 03102680A HK 03102680 A HK03102680 A HK 03102680A HK 1050486 A1 HK1050486 A1 HK 1050486A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fatty acids
- therapeutic combinations
- dgla
- therapeutic
- gla
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 6
- 229940114079 arachidonic acid Drugs 0.000 abstract 3
- 235000021342 arachidonic acid Nutrition 0.000 abstract 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 abstract 1
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 abstract 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0016045.7A GB0016045D0 (en) | 2000-06-29 | 2000-06-29 | Therapeutic combinations of fatty acids |
PCT/GB2001/002717 WO2002002105A1 (en) | 2000-06-29 | 2001-06-20 | Therapeutic combinations of fatty acids |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1050486A1 true HK1050486A1 (en) | 2003-06-27 |
Family
ID=9894724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03102680A HK1050486A1 (en) | 2000-06-29 | 2003-04-14 | Therapeutic combinations of fatty acids |
Country Status (33)
Country | Link |
---|---|
US (1) | US6479544B1 (zh) |
EP (1) | EP1296670B1 (zh) |
JP (1) | JP2004501969A (zh) |
KR (1) | KR20030016306A (zh) |
CN (1) | CN100469363C (zh) |
AT (1) | ATE315388T1 (zh) |
AU (2) | AU2001274276B2 (zh) |
BR (1) | BR0112073A (zh) |
CA (1) | CA2411368C (zh) |
CZ (1) | CZ20024173A3 (zh) |
DE (1) | DE60116625T2 (zh) |
DK (1) | DK1296670T3 (zh) |
EE (1) | EE05148B1 (zh) |
ES (1) | ES2256250T3 (zh) |
GB (1) | GB0016045D0 (zh) |
HK (1) | HK1050486A1 (zh) |
HR (1) | HRP20030035A2 (zh) |
HU (1) | HUP0301107A2 (zh) |
IL (1) | IL153458A0 (zh) |
IS (1) | IS2226B (zh) |
MX (1) | MXPA02012689A (zh) |
MY (1) | MY117830A (zh) |
NO (1) | NO329868B1 (zh) |
NZ (1) | NZ522916A (zh) |
PL (1) | PL359185A1 (zh) |
PT (1) | PT1296670E (zh) |
RU (1) | RU2276975C2 (zh) |
SK (1) | SK287209B6 (zh) |
TW (1) | TWI285549B (zh) |
UA (1) | UA76108C2 (zh) |
WO (1) | WO2002002105A1 (zh) |
YU (1) | YU99602A (zh) |
ZA (1) | ZA200300198B (zh) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
DE10006836B4 (de) * | 2000-04-18 | 2005-03-24 | Bitec Gmbh | Verwendung von Omega-3-Fettsäuren und/oder Verbindungen von Omega-3-Fettsäuren |
ITMI20010129A1 (it) | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
JP2003048831A (ja) * | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
NZ539624A (en) | 2002-09-27 | 2008-08-29 | Martek Biosciences Corp | Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
DE10254584A1 (de) * | 2002-11-22 | 2004-06-09 | HORST HEIRLER PROJEKTE für Ernährung, Medizin, Ökologie | Verwendung von mittelkettigen Triglyceriden (MCT) zur ernährungsphysiologischen Optimierung des Fettsäurenspektrums in einem diätetischen Lebensmittel für Diabetiker |
GB0311081D0 (en) | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
FR2856304B1 (fr) * | 2003-06-20 | 2006-03-03 | Natural Product Consulting | Composition pour la prevention des infections du systeme urinaire |
AU2004266480B2 (en) | 2003-08-18 | 2011-03-03 | Btg International Limited | Treatment of neurodegenerative conditions |
US7875291B1 (en) | 2003-09-05 | 2011-01-25 | Glu-Pro, Inc. | Composition for managing diabetes, obesity, and hyperlipidemia and associated methods |
JP4522075B2 (ja) * | 2003-10-29 | 2010-08-11 | サントリーホールディングス株式会社 | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
US20050249823A1 (en) * | 2003-11-04 | 2005-11-10 | Murphy Tanya K | Methods for the prevention or amelioration of neuropsychiatric and related diseases |
WO2005046668A1 (ja) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | 言語障害予防・治療剤 |
EP1543735B1 (en) * | 2003-12-20 | 2015-10-07 | Nestec S.A. | Nutritional composition for wound healing |
AU2005208832A1 (en) * | 2004-01-19 | 2005-08-11 | Martek Biosciences Corporation | Reelin deficiency or dysfunction and methods related thereto |
ATE361101T1 (de) | 2004-08-24 | 2007-05-15 | Nutricia Nv | Nahrungszusammensetzung die unverdauliche oligosaccharide enthält |
JP2006083136A (ja) * | 2004-09-17 | 2006-03-30 | Suntory Ltd | ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
US8092839B2 (en) * | 2004-12-13 | 2012-01-10 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
US8431165B2 (en) * | 2004-12-13 | 2013-04-30 | Swing Aerobics Licensing, Inc. | Medicament for treatment of cancer and other diseases |
US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
GB2421909A (en) * | 2004-12-23 | 2006-07-12 | Laxdale Ltd | Pharmaceutical compositions comprising EPA and methods of use |
US20090054523A1 (en) * | 2005-01-24 | 2009-02-26 | Morten Bryhn | Use of a Fatty Acid Composition Containing DHA for the Production of a Medical Product or a Food Stuff for the Treatment of Amyloidos-Related Diseases |
EP1852114B1 (en) | 2005-02-14 | 2019-09-18 | Suntory Holdings Limited | Composition containing dihomo-y-linolenic acid (dgla) as active ingredient |
GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
JP5967855B2 (ja) * | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
JP2009518424A (ja) * | 2005-12-09 | 2009-05-07 | ドラッグテック コーポレイション | 必須脂肪酸乳剤の静脈投与 |
GB0607949D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
EP2098229A4 (en) | 2006-12-28 | 2010-03-10 | Suntory Holdings Ltd | NERVE REGENERATION AGENT |
CA2692394A1 (en) * | 2007-07-06 | 2009-01-15 | Seth J. Baum | Fatty acid compositions and methods of use |
US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
EP4137128A1 (en) | 2008-09-02 | 2023-02-22 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same |
PT2395991E (pt) | 2009-02-10 | 2013-09-03 | Amarin Pharmaceuticals Ie Ltd | Utilização de éster etílico de ácido eicosapentaenóico para tratamento de hipertrigliceridemia |
LT3278665T (lt) | 2009-04-29 | 2020-12-10 | Amarin Pharmaceuticals Ireland Limited | Stabili farmacinė kompozicija ir jos panaudojimo būdai |
GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
EP3791880A1 (en) | 2009-04-29 | 2021-03-17 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa |
ES2856959T3 (es) | 2009-06-15 | 2021-09-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para el tratamiento del ictus en un sujeto en terapia simultánea con estatina |
RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
US20140127289A1 (en) | 2010-11-29 | 2014-05-08 | Armarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US8865685B2 (en) | 2011-06-30 | 2014-10-21 | Johnson & Johnson Vision Care, Inc. | Esters for treatment of ocular inflammatory conditions |
US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20150004224A1 (en) | 2012-01-06 | 2015-01-01 | Omthera Phrmaceuticals, Inc. | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
KR20150028233A (ko) | 2012-05-07 | 2015-03-13 | 옴테라 파마슈티칼스, 인크. | 스타틴 및 오메가-3 지방산의 조성물 |
WO2013192109A1 (en) | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
DK3363433T3 (da) | 2012-06-29 | 2021-03-08 | Amarin Pharmaceuticals Ie Ltd | Fremgangsmåder til reduktion af risikoen for en kardiovaskulær begivenhed i et individ i statinbehandling ved anvendelse af eicosapentaensyreetylester |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
KR20150103009A (ko) | 2012-12-06 | 2015-09-09 | 마티나스 바이오파마, 인코포레이티드 | 도코사펜타에노산을 포함하는 조성물의 투여 |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US20140221676A1 (en) * | 2013-02-06 | 2014-08-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating and/or preventing cardiovascular disease |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10130603B2 (en) | 2013-11-05 | 2018-11-20 | Colgate-Palmolive Company | Methods and compositions for improving kidney function |
EP3101138B1 (en) * | 2013-12-04 | 2021-05-05 | Nippon Suisan Kaisha, Ltd. | Microbial oil, method for manufacturing microbial oil, concentrated microbial oil, and method for manufacturing concentrated microbial oil |
MX2016015961A (es) | 2014-06-04 | 2017-04-05 | Dignity Sciences Ltd | Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas. |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
PT4056176T (pt) | 2018-09-24 | 2024-05-27 | Amarin Pharmaceuticals Ie Ltd | Métodos de redução do risco de eventos cardiovasculares num indivíduo |
KR20220010415A (ko) * | 2020-07-17 | 2022-01-25 | 대봉엘에스 주식회사 | 불포화 지방산을 특정 함량으로 포함하는 유지 조성물 및 이의 용도 |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US551680A (en) * | 1895-12-17 | Water-tube steam-generator | ||
US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
JPS60132916A (ja) * | 1983-12-21 | 1985-07-16 | Nisshin Oil Mills Ltd:The | 血栓症予防食品または医薬品 |
US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
GB8714772D0 (en) * | 1987-06-24 | 1987-07-29 | Efamol Ltd | Essential fatty acid compositions |
GB8813766D0 (en) * | 1988-06-10 | 1988-07-13 | Efamol Holdings | Essential fatty acid compositions |
US5260067A (en) * | 1988-11-16 | 1993-11-09 | Xu Zheng | Cytotropic heterogeneous molecular lipids (CHML) and process for preparing the same |
JPH04169524A (ja) * | 1990-11-01 | 1992-06-17 | Nissei Marine Kogyo Kk | 血清脂質改善作用を有する組成物 |
US5658767A (en) * | 1991-01-24 | 1997-08-19 | Martek Corporation | Arachidonic acid and methods for the production and use thereof |
GB9125602D0 (en) * | 1991-12-02 | 1992-01-29 | Efamol Holdings | Method of preventing reocclusion of arteries |
JPH05163142A (ja) * | 1991-12-17 | 1993-06-29 | Tokiwa Yakuhin Kogyo Kk | 肝障害の予防または治療用アラキドン酸含有組成物 |
US5223285A (en) * | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
US5516801A (en) * | 1992-08-21 | 1996-05-14 | Scotia Holdings Plc | Fatty acid treatment for ectopic calcium deposition |
GB9224809D0 (en) * | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
GB9301446D0 (en) * | 1993-01-26 | 1993-03-17 | Scotia Holdings Plc | Internal radiation damage |
GB9301629D0 (en) * | 1993-01-27 | 1993-03-17 | Scotia Holdings Plc | Formulations containing unsaturated fatty acids |
JPH06271464A (ja) * | 1993-03-19 | 1994-09-27 | Tokiwa Yakuhin Kogyo Kk | 消化器系障害の予防または治療用アラキドン酸含有組成物 |
CA2119000A1 (en) * | 1993-03-19 | 1994-09-20 | David Frederick Horrobin | Formulation for use in smokers |
AUPM906594A0 (en) * | 1994-10-26 | 1994-11-17 | Peptide Technology Limited | Synthetic polyunsaturated fatty acid analogues |
EP0711503A3 (en) * | 1994-11-14 | 1997-11-26 | Scotia Holdings Plc | Milk fortified with GLA and/or DGLA |
GB9423625D0 (en) * | 1994-11-23 | 1995-01-11 | Scotia Holdings Plc | Fortified fruit juice |
GB9617847D0 (en) * | 1996-08-27 | 1996-10-09 | Scotia Holdings Plc | Fatty acid treatment |
US5993221A (en) * | 1997-05-01 | 1999-11-30 | Beth Israel Deaconess Medical Center, Inc. | Dietary formulation comprising arachidonic acid and methods of use |
CN1212867A (zh) * | 1997-09-29 | 1999-04-07 | 宋凤亭 | 防治心脑血管疾病的组合物 |
DE19757414A1 (de) * | 1997-12-23 | 1999-07-01 | Nutricia Nv | Fettmischung |
CA2355341C (en) | 1998-10-15 | 2009-04-14 | Dsm N.V. | The use of ara as a supplement for a lactating woman |
SE9900941D0 (sv) * | 1998-12-23 | 1999-03-16 | Nomet Management Serv Bv | Novel retinoic acid derivatives and their use |
GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
-
2000
- 2000-06-29 GB GBGB0016045.7A patent/GB0016045D0/en not_active Ceased
-
2001
- 2001-06-20 WO PCT/GB2001/002717 patent/WO2002002105A1/en active IP Right Grant
- 2001-06-20 PL PL01359185A patent/PL359185A1/xx not_active Application Discontinuation
- 2001-06-20 DE DE60116625T patent/DE60116625T2/de not_active Expired - Lifetime
- 2001-06-20 CA CA002411368A patent/CA2411368C/en not_active Expired - Fee Related
- 2001-06-20 HU HU0301107A patent/HUP0301107A2/hu unknown
- 2001-06-20 MX MXPA02012689A patent/MXPA02012689A/es active IP Right Grant
- 2001-06-20 DK DK01940775T patent/DK1296670T3/da active
- 2001-06-20 PT PT01940775T patent/PT1296670E/pt unknown
- 2001-06-20 EP EP01940775A patent/EP1296670B1/en not_active Expired - Lifetime
- 2001-06-20 UA UA20021210705A patent/UA76108C2/uk unknown
- 2001-06-20 EE EEP200200718A patent/EE05148B1/xx not_active IP Right Cessation
- 2001-06-20 KR KR1020027017649A patent/KR20030016306A/ko not_active Application Discontinuation
- 2001-06-20 AU AU2001274276A patent/AU2001274276B2/en not_active Ceased
- 2001-06-20 IL IL15345801A patent/IL153458A0/xx not_active IP Right Cessation
- 2001-06-20 CN CNB01811931XA patent/CN100469363C/zh not_active Expired - Fee Related
- 2001-06-20 SK SK1816-2002A patent/SK287209B6/sk not_active IP Right Cessation
- 2001-06-20 CZ CZ20024173A patent/CZ20024173A3/cs unknown
- 2001-06-20 JP JP2002506727A patent/JP2004501969A/ja active Pending
- 2001-06-20 YU YU99602A patent/YU99602A/sh unknown
- 2001-06-20 NZ NZ522916A patent/NZ522916A/en unknown
- 2001-06-20 AU AU7427601A patent/AU7427601A/xx active Pending
- 2001-06-20 BR BR0112073-5A patent/BR0112073A/pt not_active Application Discontinuation
- 2001-06-20 RU RU2002133098/15A patent/RU2276975C2/ru not_active IP Right Cessation
- 2001-06-20 AT AT01940775T patent/ATE315388T1/de active
- 2001-06-20 ES ES01940775T patent/ES2256250T3/es not_active Expired - Lifetime
- 2001-06-21 MY MYPI20012947A patent/MY117830A/en unknown
- 2001-06-29 TW TW090116201A patent/TWI285549B/zh not_active IP Right Cessation
- 2001-06-29 US US09/893,473 patent/US6479544B1/en not_active Expired - Lifetime
-
2002
- 2002-11-29 IS IS6644A patent/IS2226B/is unknown
- 2002-12-18 NO NO20026093A patent/NO329868B1/no not_active IP Right Cessation
-
2003
- 2003-01-08 ZA ZA200300198A patent/ZA200300198B/en unknown
- 2003-01-21 HR HR20030035A patent/HRP20030035A2/hr not_active Application Discontinuation
- 2003-04-14 HK HK03102680A patent/HK1050486A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU7427601A (en) | Therapeutic combinations of fatty acids | |
DE60000133D1 (de) | Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen | |
IL129367A0 (en) | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid | |
ATE349207T1 (de) | Verstärkte wirkung mehrfach ungesättigter fettsäuren | |
EP1698685A4 (en) | FAT COMPOSITION | |
EP2258447A3 (en) | Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy | |
PT1310249E (pt) | Utilizacao de acidos gordos poli-insaturados para prevencao primaria de eventos cardiovasculares graves | |
NZ299464A (en) | Use of gamma linolenic or dihomogamma linolenic acid in the treatment of Huntington's Chorea | |
SG149825A1 (en) | Body taste improver comprising long-chain highly unsaturated fatty acid and/or ester thereof | |
CA2427289A1 (en) | Fat composition and hexacosanoic acid depressant for oral or enteral administration | |
TH76781B (th) | การรักษาโรคเบื่ออาหารเหตุจิตใจ (an) และอาการหิวไม่หาย | |
AR021830A1 (es) | Utilizacion de acido docosahexaenoico y acido araquidonico para mejorar el crecimiento de bebes anteriores a termino | |
TH76781A (th) | การรักษาโรคเบื่ออาหารเหตุจิตใจ (an) และอาการหิวไม่หาย | |
MY129218A (en) | Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid | |
RU99106551A (ru) | Применение арахидоновой кислоты и/или докозагексаеновой кислоты для получения лекарства для лечения диспраксии | |
TH60770A (th) | สารรวมกรดไขมันเพื่อใช้รักษาโรคได้ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20110620 |